Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quad-Shot Radiotherapy + Pembrolizumab in Advanced/Recurrent Head and Neck Cancer
NCT04454489Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Feb 2021
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Wake Forest University Health Sciences. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04454489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04454489.